The Cen­ters for Medicare and Med­ic­aid Ser­vices has ex­empt­ed drug­mak­ers from two pric­ing demon­stra­tion pro­grams in Medicare if they agree to pro­vide ad­di­tion­al re­bates in...

The FDA grant­ed ac­cel­er­at­ed ap­proval to a rare dis­ease gene ther­a­py from Ul­tragenyx on Thurs­day, giv­ing the com­pa­ny a much-need­ed boost in an oth­er­wise dif­fi­cult...

Bris­tol My­ers Squibb has end­ed de­vel­op­ment of a twist on the pop­u­lar an­ti­body-drug con­ju­gate field.

The Phase 1 as­set that was axed is BMS-986497/ORM-6151, ac­cord­ing...

WASH­ING­TON — What do you do when an eco­nom­ic ri­val swift­ly be­comes a crit­i­cal play­er in the in­dus­try you reg­u­late?

The FDA is com­ing to...

Six UK gov­ern­ment com­mit­tees have called for an in­ves­ti­ga­tion in­to the cost of the UK’s phar­ma­ceu­ti­cal trade deal with the US.

The let­ter, pub­lished...